ArticlePatient related outcome measures2025
Awareness of Myopia Associated Complications and Perspectives on Myopia Management Among Parents of Children with Myopia in France and the UK.
Article in Patient related outcome measures, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Parental knowledge-attitude-practice profiles in childhood myopia: a comprehensive evaluation integrated with clinical findings.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Evaluation of large language models and retrieval-augmented generation for clinical reasoning in pediatric myopia: a 50-case real-world study.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Myopia is a global public health issue, estimated to affect 50% of the world's population by 2050. Evidence suggests that reducing myopia by one diopter decreases the risk of myopia-related retinal complications by 40%. Despite the availability of several myopia control methods, their clinical adoption remains limited. To improve their uptake, enhancing parental awareness of myopia control is crucial. This study explores parental awareness of myopia-related complications, control interventions and their perspectives on myopia management in France and the UK. Patient and Methods: A structured survey was conducted among 200 self-selected parents of children with myopia (100 France, 100 UK), via the TOM app, an online platform for tracking medication adherence. The survey assessed parental understanding of myopia complications, awareness of control strategies, perspectives on management, and financial concerns. Results: 74% of French and 88% of the UK parents reported being aware of at least one myopia-related long-term complication, with cataract the most recognized in France (66%) and glaucoma in the UK (76%). 50% of French and 43% of UK parents were unsure or unaware that myopia progression could be slowed. UK parents reported higher adoption rates of myopia control methods, including orthokeratology (47% France, 68% UK), atropine (46% France, 63% UK), and red-light therapy (44% France, 67% UK). Financial burden was a significant concern, with 59% of French and 52% of UK parents feeling strained by costs, particularly for glasses, contact lenses, and specialized treatments. Parents of children with faster myopia progression (>-1 dioptres/year) were more likely to report financial stress (p<0.001). Conclusion: While most parents are aware of myopia complications, notable gaps exist in understanding control options. UK parents adopted control methods more frequently than French parents. Financial burden remains a significant concern, emphasizing the need for enhanced parental education and affordable access to myopia control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.